Amendments to the Patented Medicines Regulations delayed six months, until July 1, 2022

3 minute read
24 December 2021

Canada's recently appointed Minister of Health, the Honourable Jean-Yves Duclos, just announced the deferral of the coming into force of recent amendments to the Patented Medicines Regulations by six months, until July 1, 2022. The new Patented Medicine Prices Review Board (PMPRB) Guidelines, which operationalize the Patented Medicines Regulations, are also expected to take effect at the same time. We have previously reported on the Coming-into-Force of the amendments here (Amendments to the Patented Medicines Regulations delayed by 6-months, until July 1, 2021) and here (Amendments to the Patented Medicines Regulations delayed by a further six months, until January 1, 2022).

As previously reported, the amendments would introduce new economic factors when determining excessive pricing including pharmacoeconomic value, market size and GDP; change the basket of countries the PMPRB uses as a benchmark for pricing (most significantly removing the US and Switzerland); and introducing a new price calculation for determining non-excessive sale price. The changes would also increase the administrative burden on companies.

A statement by Minister Duclos explains that the impact of new COVID-19 variants of concern required urgent action and a further delay to the coming into force of the amendments. Specifically, this delay would allow industry and government "to continue to focus their efforts on responding to the unprecedented challenges presented by the COVID-19 pandemic." Further, in his announcement, the Minister stated that to bring these amendments into force in the context of a global pandemic "requires preparedness and consultation" and stated that a delay "also allows the Government to further engage stakeholders on the application of these amendments within the changing pharmaceutical landscape."


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Insights & Resources

Artificial intelligence robot Articles
16 August 2022 Who owns AI's IP
toronto cityscape Videos
10 August 2022 Influencers in Toronto